RT Journal Article
SR Electronic
T1 Multicenter Phase II Study of Irinotecan Plus Bolus Fluorouracil/<em>l</em>-Leucovorin for Metastasic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1003
OP 1008
VO 27
IS 2
A1 MISHIMA, HIDEYUKI
A1 IKENAGA, MASAKAZU
A1 ISHIDA, HIDEYUKI
A1 IWAMOTO, SHIGENORI
A1 MORIMOTO, TAKASHI
A1 NARAHARA, HIROYUKI
A1 KATO, TAKESHI
A1 TSUJIE, MASAKI
A1 KITAI, TOSHIYUKI
A1 FUKUNAGA, MUTSUMI
A1 NAKANISHI, MASAYOSHI
A1 TSUJINAKA, TOSHIMASA
A1 FURUKAWA, HIROSHI
A1 TAGUCHI, TETSUO
A1 OSAKA GASTROINTESTINAL CANCER CHEMOTHERAPY STUDY GROUP
YR 2007
UL http://ar.iiarjournals.org/content/27/2/1003.abstract
AB Treatment of metastatic colorectal cancer remains inadequate. Patients and Methods: In a multicentre Phase II study, irinotecan (100 mg/m2), 5-fluorouracil (5-FU) (500 mg/m2), and l-leucovorin (l-LV) (250 mg/m2) were administered on days 1, 8, and 15 of a five-week cycle. Forty-five patients were enrolled. Results: The objective response rate was 26.7%. The median survival time was 21.8 months and the one-year survival rate was 73.3%. The median number of cycles was 4.0, with a median relative dose intensity of 83.3% for both irinotecan and 5-FU. Grade 3 or 4 haematological toxicities were anaemia in four patients, leukopaenia in six patients, and neutropaenia in 15 patients, while non-haematological toxicities were diarrhoea in three patients, and nausea, vomiting, anorexia and increased transaminases in two patients each. No treatment-related deaths occurred. Conclusion: Irinotecan plus 5-FU/l-LV can be used to treat metastatic colorectal cancer on an outpatient basis. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved